Abstract 4945
Background
Cancer of unknown primary origin (CUP) represents a metastatic cancer with unidentified primary origin. An efficient cancer treatment algorithm is based on detection and characterization of the tumor’s origin. CUP is characterized by chromosomal instability; therefore the detection of chromosomal aberrations might contribute in tumor characterization. aCGH combines DNA microarray with CGH providing better detection rates than conventional cytogenetic methods. The present study aimed to evaluate aCGH as a technique for detection the origin of tumor, based on liquid biopsy and particular in circulating tumor cells.
Methods
Blood samples were collected from five patients suffering from prostate (2), lung (2) and breast (1) cancer and five healthy individuals. CTCs isolated using enrichment protocols while CD45 (-ve) cells isolated from healthy individuals. In addition to patients’ samples, six commercial cancer cell lines provided by ECACC were used, representing prostate and lung cancer (DU145, 22Rv1, LNcaP, COLO699N, COR0L 105 and MOR). Genomic DNA extracted and aCGH experiments followed with Sureprint G3 platform (Agilent). The genes located in chromosomal aberrations were literately analyzed and potential cancer type suggested by another researcher. The researcher performed the analysis based only on aCGH raw data, ignoring the identity and medical history of all samples. Samples firstly analyzed based on normal vs cancer prediction and secondly whether the predicted type of cancer was correct.
Results
The sensitivity was around 90% while the specificity was 80%. Among eleven cancer samples only one predicted as normal, as well as one normal sample predicted as cancer. As far as the cancer type prediction the positive predictive value was 90.1%. Only one sample categorized wrongly in total cancer samples.
Conclusions
aCGH is a powerful technique with potential of discrimination of cancer and healthy samples, but most important with ability to distinguish the type of cancer. The identification of primary origin of cancer is very important in CUP, since it is correlated with more efficient treatment algorithm. The above encouraging data from the combination of aCGH and liquid biopsy need to be validated in more samples and types of cancer so to be used at clinical level.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Research Genetic Cancer Centre S.A.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2436 - Development and Validation of an RNA-Seq Assay for Gene Fusions Detection in Formalin-Fixed Paraffin-Embedded Samples
Presenter: Hua Dong
Session: Poster Display session 3
Resources:
Abstract
5271 - A Pilot Study to Implement an Artificial Intelligence (AI) System for Gastrointestinal Cancer Clinical Trial Matching
Presenter: Zhaohui Jin
Session: Poster Display session 3
Resources:
Abstract
4787 - A Blinded Comparison of Patient Treatments to Therapeutic Options Presented by an Artificial Intelligence-based Clinical Decision-support system
Presenter: Suthida Suwanvecho
Session: Poster Display session 3
Resources:
Abstract
5744 - OncOS: scalable and accurate next-generation sequencing analytics for precision oncology and personalized patient care
Presenter: Joe Thompson
Session: Poster Display session 3
Resources:
Abstract
3752 - The association between wearable device physical activity metrics and performance status in oncology: a systematic review
Presenter: Milan Kos
Session: Poster Display session 3
Resources:
Abstract
5820 - SomaticNET: neural network evaluation of somatic mutations in cancer
Presenter: Geoffroy Dubourg-Felonneau
Session: Poster Display session 3
Resources:
Abstract
4771 - Is there a role for Next-generation sequencing (NGS) profiling on metastatic non-colorectal gastrointestinal carcinomas (MNCGIC) in developing countries? A single center experience.
Presenter: Mauricio Ribeiro
Session: Poster Display session 3
Resources:
Abstract
1209 - Metastatic Cancer Whole-Exome Sequencing in daily practice
Presenter: Manon Réda
Session: Poster Display session 3
Resources:
Abstract
5702 - Genomic-Guided Individualized Precision Therapy in Refractory Metastatic Solid Tumor Patients with Extensively Poor Performance Status: A Chinese single institutional prospective observational real-world study
Presenter: Haitao Wang
Session: Poster Display session 3
Resources:
Abstract
4021 - Prospective pathological experience with research biopsies in the context of clinical trials at Vall d’Hebron Institute of Oncology
Presenter: Paolo Nuciforo
Session: Poster Display session 3
Resources:
Abstract